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Systemic autoimmune rheumatic diseases (SARDs) are chronic inflammatory and immuno-modulatory conditions that have been
suggested to affect cancer risk. Using the Surveillance, Epidemiology and End Results–Medicare-linked database, women aged 67–99
years and diagnosed with incident breast cancer in 1993–2002 (n¼84778) were compared with an equal number of age-matched
cancer-free female controls. Diagnoses of SARDs , including rheumatoid arthritis (RA, n¼5238), systemic lupus erythematosus (SLE,
n¼340), Sjogren’s syndrome (n¼374), systemic sclerosis (n¼128), and dermatomyositis (n¼31), were determined from claim files
for individuals from age 65 years to 1 year before selection. Associations of SARD diagnoses with breast cancer, overall and by
oestrogen receptor (ER) expression, were assessed using odds ratio (OR) estimates from multivariable logistic regression models.
The women diagnosed with RA were less likely to develop breast cancer (OR¼0.87, 95% confidence interval (CI)¼0.82–0.93).
The risk reduction did not differ by tumour ER-status (OR¼0.83, 95% CI¼0.78–0.89 for ER-positive vs OR¼0.91, 95% CI¼0.81–1.04
for ER-negative, P for heterogeneity¼0.14). The breast cancer risk was not associated with any of the other SARDs, except for a risk
reduction of ER-negative cases (OR¼0.49, 95% CI¼0.26–0.93) among women with SLE. These findings suggest that systemic
inflammation may affect breast epithelial neoplasia.
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Breast cancer (BC), the commonest malignancy and the second
leading cause of cancer death among American women (American
Cancer Society, 2007), is heterogeneous, particularly with respect
to expressions of oestrogen and progesterone receptors. Oestrogen
receptor (ER) status is of special interest because of its clinical
implication (Andry et al, 1989; Hess et al, 2003). The fact that
known BC risk factors account for only 45–55% of the cases
(Willett et al, 2004) indicates the need for further research.
Systemic autoimmune rheumatic diseases (SARDs) predominantly
affect women (Cooper and Stroehla, 2003). They include rheuma-
toid arthritis (RA), systemic lupus erythematosus (SLE), Sjogren’s
syndrome, systemic sclerosis, and dermatomyositis (Marrow et al,
1999). Typically, these are associated with activation of auto-
reactive T and B lymphocytes and release of pro-inflammatory
cytokines, which may alter cancer risk (Salazar-Onfray et al, 2007).
Several studies of SARDs and breast cancer risk have had
inconsistent results (Hill et al, 2003; Chatterjee et al, 2005; Derk
et al, 2006; Kontos and Fentiman, 2008; Smitten et al, 2008), which
may reflect limitations such as small sample size, short time of
follow-up, selection bias in hospital-based cohorts, detection bias,
or reverse causality with a short interval between SARD diagnoses
and BC. In addition, if any BC risk associated with SARDs is
ER-specific, the distribution of ER status in the studied popula-
tions might lead to conflicting results.
We conducted a population-based case–control study using the
Surveillance, Epidemiology and End Results (SEER)–Medicare-
linked database to evaluate whether a history of SARD diagnoses
was associated with BC risk overall and by ER status of the tumour.
SUBJECTS AND METHODS
The SEER–Medicare data linkage, a collaboration of the National
Cancer Institute and the Center for Medicare and Medicaid
Services, was created by linking two large population-based data
sources: the SEER cancer registry system and the Medicare
enrolment and claim files. Detailed description of the database is
available elsewhere (Warren et al, 2002). Briefly, it includes all
incident cancer cases recorded by SEER registries, currently
encompassing B25% of the US population, plus a 5% random
sample of all Medicare beneficiaries residing in SEER areas to serve
as population-based controls. The Medicare part of the linkage
includes data from inpatient claims since 1986 and from all other
types of claims (outpatient, physician, home health, and hospice
services) since 1991. The database does not include claims for
Medicare beneficiaries during enrolment in a health maintenance
organisation (HMO). Clinical diagnoses are coded using the
International Classification of Diseases, 9th Revision (ICD-9)
codes (US Public Health Service, 1996).
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primary invasive adenocarcinoma of the breast (ICD-O-3 C500-
C509; histology codes 8140, 8201, 8211, 8480, 8500, 8501, 8503,
8504, 8520, 8521, 8522, 8523, 8524, 8530, 8541, and 8543; and
behaviour code 3) who were diagnosed in 1993–2002, with no
previous cancer of any type; BC cases diagnosed only at autopsy or
by death certificate were excluded.
Female controls who were alive and cancer free as of 1 July of the
calendar year of case selection were selected at random, with
replacement, from the 5% sample of the Medicare beneficiaries
who resided in SEER areas. To ensure availability of claims data,
cases and controls had to be 67–99 years of age, selected in 1993 or
later, and have at least 12 months of simultaneous part A and B
coverage (and no HMO coverage) before the selection date.
Controls were frequency matched in 1:1 ratio to cases according
to the calendar year of diagnosis and age in three categories
(67–74, 75–84, and 85þ). Women who became BC cases could be
selected as controls until they were diagnosed with the cancer.
Participants were considered to have SARDs if they had at least
one inpatient or two outpatient/physician claims (with a minimum
interval of 30 days between claims) for any of the following
diagnoses: RA (ICD-9 714.0, 714.1, 714.2, 714.3, 714.81, or V82.1),
SLE (710.0), systemic sclerosis (710.1), Sjogren’s syndrome (710.2),
or dermatomyositis (710.3). Women who met the definition for
more than one condition were included in a separate category,
multiple SARDs. History of SARDs was ascertained from Medicare
claim files, up to 12 months before case–control selection date.
Variables assessed as potential confounders of associations
between BC and SARDs included age, race, socio-economic status,
region of residence, history of mammography, number of
physician visits 12–24 months before selection, and earlier use
of immunosuppressive medications. We used the 1990 census
median annual household income in the study participants’ zip
code of residence as a proxy measure of individuals’ socio-
economic status. The regions of residence, based on the location of
the SEER registry, were categorised as western, northeastern,
north-central, and southern (Table 1). History of mammography
was defined as any mammography claim recorded from 12 months
to a maximum of 48 months before case–control selection. History
of immunosuppressive therapy was defined as any Medicare claim
for the following between age 65 years and 12 months before the
case–control selection: cyclophosphamide, methotrexate, chlor-
ambucil, azathioprine, cyclosporine, mycophenolate mofetil,
sirolimus, tacrolimus, prednisone, prednisolone, methyl predniso-
lone, and immunosuppressive medication not otherwise specified.
Statistical analysis
We used unconditional logistic regression to calculate odds ratios
(ORs) and 95% confidence intervals (CIs) for the association
between BC risk and SARDs (overall and for each condition). We
computed the variance of the OR estimates using a robust variance
estimator (Zeger and Liang, 1986) to adjust for the correlations
between observations when the same participant was selected in
different calendar years.
In evaluating BC risk by ER status, we excluded cases with
unknown ER expression. We used polytomous logistic regression
to estimate ORs and 95% CIs with a robust variance estimator
comparing ER-positive cases and ER-negative cases with the
cancer-free controls (Anderson et al, 2008). A Wald test with one
degree of freedom was used to test for the heterogeneity in the
estimated regression coefficient for specific SARDs between
ER-positive and ER-negative cases.
All final models were adjusted for age and year of selection
(matching variables), race, region of residence, median-household
income by zip code of residence, history of mammography, and
history of immunosuppressive therapy as defined earlier. We also
stratified all the models by year of selection in three groups
(1993–95, 1996–99, and 2000–02) to investigate whether the
estimated associations were affected by secular trends in coding
accuracy, mammography screening, or standard of care. In the
final models that evaluated overall BC risk associated with SARDs
(overall and by condition), we added two interaction terms, age
(X75 vs o75) and race (whites vs others), to test whether these
associations are modified by age or race.
RESULTS
The study included 84778 BC cases and an equal number of
cancer-free controls. Most of the cases (78.2%) had known ER
status, of whom 84.9% were ER-positive. As shown in Table 1,
cases and controls had similar age distribution (median¼67
years), region of residence, duration of Medicare coverage
(median¼101 vs 102 months, respectively), and number of visits
to physicians from 12 to 24 months before case–control selection
(median¼12 vs 11 visits, respectively). However, more cases than
controls were white (88.4 vs 83.7%), and had history of
mammography 12–48 months before selection (50.5 vs 45.4%).
Patterns were similar for ER-positive and ER-negative cases, with
the exception of race, for which more ER-negative cases than
controls were black (9.4 vs 7.7%) (Table 1).
Breast cancer cases with unknown ER status were similar to
those with known status with respect to SARD distribution, but
they were more likely to be diagnosed between 1993 and 1995 (26.5
vs 21.4%), have tumours of unknown grade (25.3 vs 12.3%), have
non-specific morphology (10.8 vs 1.5%), and no recorded stage
(5.6 vs 0.7%). Although statistically significant, absolute differ-
ences between cases with known and unknown ER status with
respect to age, race, and income were small (o5%) (Supplemen-
tary Table S1).
Of all participants, 4.0% (n¼3033 in BC cases and 3396 in the
controls) met the study definition of at least one SARD condition.
Among them, 95.2% had only one condition. Of those who had
been diagnosed with more than one condition, 84.6% had RA.
In unadjusted analyses, history of having any SARD diagnosis
was inversely associated with breast cancer risk (OR¼0.89, 95%
CI¼0.84–0.93). When comparing individual SARD cases with no
SARD cases, only RA was significantly associated with a decreased
BC risk (OR¼0.87, 95% CI¼0.82–0.92) (data not shown).
Multivariable regression models showed similar results (Table 2).
Similar results were also obtained when we stratified the models by
year of selection (data not shown). No significant interactions were
found with age or race in the association between BC and SARD
(overall or for individual condition, data not presented).
When comparing ER-positive and ER-negative cases with
cancer-free controls in unadjusted analysis, RA was inversely
associated with both ER-positive and ER-negative BC risk
(OR¼0.83, 95% CI¼0.78–0.89, and OR¼0.90, 95% CI¼0.80–
1.03, respectively), whereas SLE was inversely associated only with
ER-negative tumours (OR¼0.50, 95% CI¼0.27–0.95) (data not
shown). Multivariable analysis showed similar results (Table 2).
Heterogeneity in the estimated ORs of ER-positive and ER-
negative BC associated with SARDs was only significant in the case
of SLE (OR¼1.08, 95% CI¼0.85–1.40, and OR¼0.49, 95%
CI¼0.26–0.94, respectively, P¼0.02). Results obtained from
stratified models by year of case–control selection and unstratified
models were similar, except for an attenuation of the risk deficit
for ER-positive BC with RA in recent years (OR¼0.76, 0.83, and
0.85 for 1993–1995, 1996–1999, and 2000–2002, respectively, P for
trend o0.0001) (Supplementary Table S2).
DISCUSSION
Our study found a reduced BC risk associated with RA that did not
differ by the ER-status of the tumour. We also observed a reduced
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None of the other SARDs investigated was associated with BC risk
overall or by ER status.
Our observed association for RA agrees with the results of a
recent meta-analysis that reported a pooled standardised incidence
ratio of 0.84 (95% CI¼0.79–0.90) for breast cancer among women
with RA (Smitten et al, 2008). For SLE, our results are consistent
with the overall null associations reported by studies that recruited
a wide spectrum of SLE patients (Cibere et al, 2001; Ragnarsson
et al, 2003), but they contrast with the protective effect observed in
studies that recruited the SLE patients from inpatient records or
tertiary care units, which are likely to over-represent severe SLE
cases (Bjornadal et al, 2002; Bernatsky et al, 2005). Perhaps disease
activity, severity, or treatment affects its relationship to BC risk.
No earlier study evaluated this association by the tumour
ER-specific subtypes.
The variation in BC risk with different SARD conditions might
reflect differences in cytokine profiles. For example, high circulating
levels of tumour necrosis factor-alpha (TNF-a)a n dt r a n s f o r m i n g
growth factor-beta (TGF-b) have been reported in patients with RA
(Arend and Gabay, 2004), but not in patients with Sjogren’s
syndrome (Garcic-Carrasco et al, 2001; Eriksson et al, 2004). Both
TNF-a and TGF-b have been reported to suppress breast cancer cell
proliferation, predominantly against ER-positive cells (Sgagias et al,
1991; Grimm and Rosen, 2006). On the other hand, SLE patients
(Lub-de Hooge et al, 2005; Rus et al, 2005), and to a lesser extent RA
patients (Xie et al, 2007), have elevated serum levels of TNF-related
apoptosis-inducing ligand (TRAIL). TRAIL has been shown to
Table 1 Characteristics of breast cancer cases (overall and by ER status) and controls
Controls
(N¼84778)
All cases
(N¼84778)
ER-positive cases
a
(N¼56296)
ER-negative cases
a
(N¼9991)
%
Age in years (median) (76.0) (76.0) (76.0) (75.0)
67–70 19.2 19.1 19.2 21.3
71–75 28.0 28.3 28.6 29.4
76–80 24.9 25.3 25.8 24.4
81–84 14.6 13.9 16.4 15.2
85+ 13.3 13.3 10.1 9.7
Race
White 83.7 88.5 89.8 84.7
Black 7.7 6.4 5.2 9.4
Hispanic 2.4 1.3 1.2 1.5
Others/unknown 6.2 3.8 3.8 4.4
Region of residence
b
Western 51.2 51.3 52.8 47.9
Northeastern 17.0 17.6 16.6 18.8
North-central 20.1 20.1 20.0 21.1
Southern 11.7 11.0 10.6 12.2
Income
c
o$25000 20.8 18.7 18.3 20.2
$25000–$34999 28.1 28.1 28.5 28.2
$35000–$49999 32.4 33.0 33.0 32.4
X$50000 13.2 14.0 14.2 13.4
Unknown 5.4 6.2 6.0 5.8
Selection year
1993–1995 22.5 22.5 21.1 23.3
1996–1999 31.5 31.5 31.9 32.5
2000–2002 46.0 46.0 47.0 44.2
Mammography
d
Yes 45.4 50.5 52.0 48.7
No 54.6 49.5 48.0 51.3
Months of coverage
e (median) (102.0) (101.0) (102.0) (98.0)
12–23 3.2 3.2 3.3 3.1
24–59 19.2 19.2 19.3 21.1
60+ 77.6 77.6 77.4 75.8
Number of physician visits
f (median) (11.0) (12.0) (12.0) (12.0)
0 16.0 15.3 15.2 15.2
1–11 36.7 35.2 35.3 36.8
12–23 23.2 24.4 24.7 23.4
24+ 24.1 25.1 24.8 24.6
aER status is missing for 18491 breast cancer cases
bWestern region includes Hawaii, New Mexico, San Francisco, Seattle, Utah, San Jose, Los Angeles, and Greater California;
North eastern region includes Connecticut and New Jersey; North-central includes Detroit and Iowa; Southern region includes Atlanta, rural Georgia, Kentucky, and Louisiana.
cMedian household income by residential zip code.
dEver had mammography 12–48 months before case–control selection.
eNumber of months of total simultaneous coverage
part A, B, and non-HMO.
fNumber of visits to a physician 12–24 months before case–control selection.
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(Rahman et al, 2009), perhaps explaining our observed reduced risk
of ER-negative, but not of ER-positive, breast cancer in women with
SLE. Although plausible, we were not able to rule out the possibility
that the observed inverse association with RA might be confounded
by the use of nonsteroidal anti-inflammatory drugs (NSAIDs). The
NSAIDs seem to have a protective effect against BC (Coogan et al,
1999; Johnson et al, 2002; Harris et al, 2003; Takkouche et al, 2008).
However, the generally null associations with SARD conditions, with
the notable exception of RA, suggest that use of NSAIDs does not
explain the observed associations.
Possible differences in known BC risk factors that were not
available in our study, such as parity, age at first birth, obesity,
alcohol consumption, and use of hormone therapy, should also be
considered. It seems unlikely that they completely explain the
observed associations, as these are the risk factors for ER-positive,
but not for ER-negative tumours (Chen and Colditz, 2007). In
addition, the low body mass index (BMI) prevalent in women with
RA is mainly because of muscle wasting rather than low body fat
(Munro and Capell, 1997), and thus is less likely to affect levels of
endogenous oestrogens, which are thought to mediate the
association between BMI and BC. Also, these factors did not
completely confound the association between SLE and BC in an
earlier study (Bernatsky et al, 2003).
Our study strengths include population-based sampling of the
participants and a large sample size. The SEER–Medicare-linked
database allowed the identification of incident breast cancer cases
and provided detailed tumour information. In addition, we captured
SARD conditions from inpatient, outpatient, and physician claims,
minimising selection bias by capturing the whole spectrum of the
diseases, including the one-quarter of SARD patients who were
treated only as outpatients. Exclusion of the 1 year before case–
control selection minimised the possibility of reverse causality and
detection bias that could result from increased medical surveillance
around the time of cancer diagnosis.
Study limitations include the lack of information on important
BC risk factors such as obesity and parity, as well as detailed
medical information about the SARD conditions, including
severity, duration, and detailed treatment history. We adjusted
for the use of immunosuppressive medications; however, under-
estimation of the actual use is expected, especially for the less
expensive oral medications, such as corticosteroids, because of the
medication coverage rules of Medicare. The missing information
on ER expression for one-fifth of the BC cases might be a source of
bias. However, the equal distribution of SARD conditions in BC
cases with known and unknown ER status suggests that substantial
differential bias is unlikely.
In conclusion, this study provides evidence for a reduced risk of
BC in older women with RA and also suggests that older women
with SLE may be at reduced risk for ER-negative BC, suggesting a
possible role for systemic mediators of inflammation and
immunity against BC cells.
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